AMED241220C50000
- 0.00
- 0.000.00%
Amedisys Newsroom
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape
UnitedHealth's $33B Deal With Hospice Provider Blocked By DOJThe Deal Values Amedisys at $101 a Share
Express News | UnitedHealth Says 'Will Vigorously Defend Against The DOJ's Overreaching'
UnitedHealth's Effort to Buy Another Home Health Provider at Risk Amid DOJ Lawsuit
Express News | Optum - Will Vigorously Defend Against Doj’s Legal Action Aimed at Blocking Proposed Deal of Optum and Amedisys
Sector Update: Health Care Stocks Slipping Tuesday Afternoon
News Highlights: Top Company News of the Day - Tuesday at 1 PM ET
Top Midday Decliners
Express News | Amedisys Shares Down 1.6%
Top Midday Stories: Tyson Foods Reports Q4 EPS, Revenue Beats; DOJ Reportedly Moving to Block UnitedHealth's Amedisys Acquisition
Market Chatter: DOJ Moving to Block UnitedHealth's $3.3 Billion Acquisition of Amedisys
Express News | US Justice Department Preps Suit Over UnitedHealth-Amedisys Deal - Bloomberg News
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
Amedisys | 10-Q: Q3 2024 Earnings Report
Amedisys: Q3 Earnings Snapshot
Amedisys Q3 2024 Revenue Rises Amid Merger Talks
Amedisys Q3 EPS $1.00 Misses $1.17 Estimate, Sales $587.70M Beat $586.49M Estimate